FeyeCon manufactures cannabinoid Active Pharmaceutical Ingredients (API’s). FeyeCon holds API and GMP license for production and sales of CBD (Cannabidiol) and THC (Tetrahydrocannabinol, also known as Dronabinol). CBD and THC API are isolated from the Cannabis Sativa plant, grown under controlled conditions. Next to these well know API’s product pipeline is expanding with new APIs, always by isolation and purification from botanical plants and not synthesizing.
Product pipeline
Cannabidiol (CBD)
Commercialisation
Dronabinol* (THC)
Commercialisation
Tetrahydrocannabinolic acid (THCA)
Implementation
Cannabigerol (CBG)
Development
Cannabidiravin (CBDV)
Development
Since 2002 when FeyeCon received its first cannabis license, extensive R&D has been done on the field of cannabinoids. Over the years FeyeCon has gain extensive knowledge on isolation and formulation of cannabinoids. Therefore, next to the API’s FeyeCon can also assist in the formulation of the API’s, we have second to none experience in this field. We are the original designers of THC tables with shelf-life over two years. Our commercial arm in the field is Folium Europe.
FeyeCon holds the pharmaceutical GMP license since 2006 and holds an Opiate license since 2002 for cannabis and THC. Moreover, in 2022 FeyeCon was granted with an opiate license for Psilocybin.
FeyeCon has a full GMP production team and a dedicated Quality Assurance manager. Next to the production of cannabinoids API’s, FeyeCon uses its GMP license also to produce medical devices as Contract Manufacturer (CM).
